2015. Second-line treatment with Axitinib: an effective and well-tolerated weapon in the therapeutic sequence of clear cell renal cell carcinoma. Working Paper of Public Health. 4, 1 (Jun. 2015). DOI:https://doi.org/10.4081/wpph.2015.6697.